Lazarus Announces Launch of Clinical Decision Support Platform That Uses A.I. & Deep Learning to Improve Early Cancer Detection
Detecting skin cancer has become more simple and accurate thanks to Lazarus CDS. The new platform greatly aids early analysis for Primary Care Doctors.
CAMBRIDGE, Mass., Oct. 17, 2019 /PRNewswire-PRWeb/ -- The early detection of skin cancer can be crucial in a patient receiving the right treatment before it progresses further. With many patients first seeing a primary care doctor when physical signs of skin cancer show, resources that can help their correct identification of skin cancer be extremely valuable. Enter technology company focused on finding cancer Lazarus. Lazarus recently announced the launch of their new app and platform that combines powerful Artificial Intelligence and Deep Learning, to deliver a tool which uses 300K images plus patient records to instantly identify skin cancer. The early response to the new Lazarus platform has been remarkably enthusiastic. The Lazarus launch is in partnership with EPIC System's App Orchard program.
"We're excited about what this means for medicine," commented a spokesperson from Lazarus. "Never before has a primary care doctor been able to meet or exceed the performance of a specialist in the diagnostic step. With Lazarus CDS, they're now able to do that."
According to Lazarus, works immediately out of the box, without any complicated installs or steep learning curves. It is both secure and transparent, fully HIPAA compliant with SOC-1 and SOC-2 certification, and complete reporting and performance monitoring for enterprises clients.
The skincare identification resource is used with just a smartphone and dashboard. This gives both primary care doctors and dermatologists a way to quickly and accurately screen for skin cancer with just one photo.
This ability to get a quick and simple diagnosis not only expands what primary care doctors and dermatologists are able to accurately deliver, but also ends up saving time, peace of mind, and money for patients, who have one full step removed from the "old school" way skincare would normally be confirmed or dismissed for patients.
In clinical testing, Lazarus has a 93% accuracy rate, with, so far, 72 thousand patients tested, 2300 models built, and nearly 4 million patients records.
Lazarus CDS connects to ten different EHRs, that covers over 95% of all patient populations – more than double the coverage of the largest competing platform.
Early feedback for the app and platform has been very positive across the board.
Scott S., from Boston, recently said, "We have found Lazarus CDS incredibly valuable in our dermatology office. It has made us more useful to patients, while providing them a better service. A total win-win and fully recommended."
SOURCE Lazarus
Share this article